Background-Determining the pathogenesis of sudden cardiac arrest or periarrest without significant coronary artery disease is crucial for management and prognosis. Cardiovascular magnetic resonance (CMR) can detect morphological, functional, or tissue abnormalities, and we sought to evaluate the role of CMR in determining sudden cardiac arrest pathogenesis and prognosis in survivors. Methods and Results-We retrospectively reviewed cardiac investigations and clinical outcomes in consecutive survivors of potentially fatal arrhythmias without coronary artery disease admitted to our institutions from 2008 to 2014. After coronary angiography and echocardiography, all underwent CMR and, when indicated, electrophysiology studies. Major adverse cardiac events (MACE), comprising significant nonfatal ventricular arrhythmia or death, was the primary outcome. Of 164 included subjects (65% men; mean age 48 [18-80] years), CMR contributed to the diagnosis in 80 (49%) and was decisive in 50 cases (30%). Dilated cardiomyopathy (n=27), myocarditis or sarcoidosis (n=22), occult myocardial infarction (n=13), and hypertrophic cardiomyopathy (n=9) were most frequent. Arrhythmic causes were found in 14% while no cause was identified in 36%. MACE occurred in 31% of subjects during a median follow-up of 32 months. MACE associated with presence of a CMR diagnosis, extent of late gadolinium enhancement, and left and right ventricular ejection fractions. Right ventricular ejection fraction was an independent predictor of MACE. Conclusions-CMR identified a likely pathogenesis for sudden cardiac arrest in nearly half of survivors in whom coronary artery disease had been excluded. One in 3 subjects had MACE; risk doubled in those with a CMR diagnosis and some CMR parameters-late gadolinium enhancement, left ventricular ejection fraction, and especially right ventricular ejection fraction-associated with prognosis. (Circ Cardiovasc Imaging.
S
urviving sudden cardiac arrest (sCA) or a periarrest event is increasingly likely in societies investing in emergency response capabilities. 1 In the absence of coronary artery disease (CAD), determining the pathogenesis of sCA is often challenging.
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Although most sCA survivors receive implantable cardiac defibrillators (ICDs), other aspects of their management and prognosis will depend on the underlying cause.
In addition, although recurrent arrhythmia rates are high after the index sCA, some causes of sCA may be transient and only temporary secondary arrhythmia prevention may be needed-as indicated in the case of cardiac arrest immediately after an acute myocardial infarction. 6 Finally, inherited cardiac conditions are frequently identified as causes of sCA, and an accurate diagnosis is essential for genetic testing and for family counseling and screening. 7, 8 Notably, most studies of sCA include patients both with and without CAD. In those excluding coronary disease, the majority are postmortem studies in nonsurvivors 2, 9, 10 or focus only on the young and athletes. For example, diagnoses based on electrophysiology studies and dynamic ECG changes can be missed, 11 as well as those sensitive to sampling errors. 12 Cardiovascular magnetic resonance (CMR) can detect subtle structural, functional, and tissue abnormalities of the cardiac muscle; in combination with other assessments, CMR can increase our ability to diagnose many of diseases affecting the heart muscle that are most commonly associated with sCA. 13, 14 Alongside, late gadolinium enhancement (LGE; both the presence and extent) has been found to be prognostic across a variety of cardiac diagnoses [15] [16] [17] [18] and clinical settings, including cardiac arrest survivors. 13 CMR is, therefore, likely to have an additional role in determining the substrate for the ventricular arrhythmias in sCA survivors and for identifying those patients at greatest risk of recurrent arrhythmias. 14, 19, 20 Our aims were therefore to 1. Provide a contemporary description of the noncoronary causes of sCA, their relative frequency in an adult population, and estimate the frequency with which this carries implications for patient and family management. 2. Describe the diagnostic use of a clinical strategy based on CMR for the evaluation of adult sCA survivors without coronary disease. 3. Assess the prognostic use of CMR findings (LGE in particular) in this population of adult sCA survivors.
Methods
The data that support the findings of this study are available from the corresponding authors on reasonable request.
Study Population
We retrospectively studied consecutive patients admitted at the London Chest and University College London Hospitals National Health Service Trusts between 2008 and 2014 (now part of Barts Heart Centre, Barts Health NHS Trust), who survived a resuscitated cardiac arrest or sustained ventricular tachycardia with hemodynamic instability requiring emergent cardioversion (a periarrest scenario) between 2008 and 2014. All subjects underwent coronary angiography and those without significant CAD (luminal obstruction <30%) and that underwent CMR were included in this study. If an underlying cause was not identified from the CMR or if the ECG raised concern on a primarily arrhythmic cause, electrophysiology assessment was made, including ECG analysis, sodium channel blockade, catecholamine infusion, treadmill test, and electrophysiology studies, where deemed clinically indicated. The final clinical diagnosis (considered the cause of the sCA) was made during the index admission by the cardiology team managing the patient, using all available data (clinical, imaging, and electrophysiological).
Consent and Ethical Approval
This study was conducted as audit (Clinical Management of the Inherited and Acquired Heart Muscle Diseases, Barts Health NHS Trust audit No. 5298). All clinical data were collected as part of standard care, and all patient identifiable fields were removed before analysis.
CMR Protocol
All CMR studies were undertaken during the index admission after cardiac arrest. Scanning was performed on Philips and Siemens 1.5 Tesla scanners. All protocols included cine imaging and LGE imaging. T1-weighted imaging pre-and post-contrast and T2-weighted triple inversion recovery images (short tau inversion recovery) were acquired where deemed clinically indicated.
Left ventricular dimensions, mass, and systolic function were assessed using steady-state free precession cine imaging. LGE images were acquired 10 minutes post-injection of 0.1 mmol/kg gadoterate meglumine (Dotarem Guerbet S.A. France) with an inversion recovery-segmented gradient echo (Turbo-Flash) sequence, with slice orientations corresponding to the cine images. In patients with limited breath-holding ability or frequent ectopy, a single-shot steady-state free precession-based inversion recovery sequence was used.
A quantitative evaluation of edema was obtained from T2-weighted short tau inversion recovery images by measurement of myocardial signal intensity normalized to skeletal muscle in the same slice. 21 Quantitative evaluation of the early gadolinium enhancement ratio, a marker of hyperemia, analyzed from T1-weighted spin echo images, was obtained by measuring the signal intensity before and after contrast administration and normalized to the skeletal muscle. 21 All studies were analyzed by 2 investigators blinded to the original CMR results, final clinical diagnosis, and outcomes in a central core laboratory using CVI42 software (Circle Cardiovascular Imaging, Calgary, AB, Canada). Standard volumetric analysis was performed (papillary muscles included as myocardium) and measurements indexed to body surface area.
LGE was automatically quantified using a threshold of 5 SDs above the mean signal intensity of the remote myocardium. 22 The site of enhancement was classified as subendocardial/transmural (ischemic) or as epicardial/midwall/patchy (nonischemic). Small or poorly defined patches of LGE (≤1% of total myocardium) were considered nonspecific.
Final CMR diagnosis was obtained by consensus between at least 2 investigators.
We followed the current criteria for defining arrhythmogenic right ventricular dysplasia, 23 dilated cardiomyopathy, 24 hypertrophic cardiomyopathy, 25 and myocarditis, 21 as published elsewhere.
Final Clinical Diagnosis
We defined final clinical diagnosis as the cause of the sCA deemed responsible for the episode adjudicated by the medical team treating the patient based on all clinical information available (imaging, electrophysiological, biopsy, genetic). This did not need to coincide with the final CMR diagnosis.
Outcome Assessment
The primary end point was the occurrence of major adverse cardiac events (MACE), defined as a composite of significant nonfatal ventricular arrhythmia (appropriate antitachycardia pacing or ICD shock, sustained ventricular tachycardia, or ventricular fibrillation) and death. Clinical outcome information was obtained from electronic health records, with mortality data from linked national databases, including NHS Spine. Follow-up arrhythmia data were obtained from ICD interrogation and from medical records.
Statistical Analyses
Continuous data are described as mean±SD or median (25-75 interquartile range) for non-Gaussian distributions. Shapiro-Wilk test was used to assess normality. Categorical data are presented as absolute frequencies (n) and percentages.
Baseline differences between patients with and without MACE were assessed using univariable Cox regression analysis.
The hazard ratio for the prediction of the events was calculated for MACE using Cox regression models. Multivariable analysis was performed using Cox regression with a stepwise forward selection method. Parameters that were significantly associated with MACE in the univariable analysis (P<0.1) and without collinearity were considered. Sex and age were also included because of their known clinical significance and impact on survival.
Survival analysis was completed with event curves, described according to the Kaplan-Meier method, and comparison of event rates was performed using the log-rank test.
We used SPSS software (version 20) for statistical analyses, considering 2-sided tests with P<0.05 for statistical significance.
Results
We included 164 patients, 65% (107) were men, with a mean age at presentation of 48±15 years (range, 18-80 years). Baseline characteristics are presented in Table 1; 9 patients had an arrest with a nonshockable rhythm (pulseless electric activity or asystole), 20 had sustained ventricular tachycardia with hemodynamic instability (a periarrest scenario), and the remaining 135 had pulseless ventricular tachycardia or ventricular fibrillation.
An ICD was placed in 70% (n=114). Follow-up data were available in all but one of the subjects.
CMR Findings and Diagnoses
The main parameters analyzed in CMR imaging are described in Table 2 .
Indexed cardiac volumes were normal in 71% of subjects, and median left ventricular ejection fraction (LVEF) was 59 (interquartile range, 47-68), with 31.7% of the subjects presenting LVEF ≤50% (17.7% had LVEF 40%-50%; 7.3% had LVEF 30%-40%, and 6.7% had LVEF ≤30%).
Tissue Characterization With LGE
Abnormal LGE was detected in 61 (37%) of subjects-of these, it was predominantly subendocardial or transmural in 34% (n=21), midwall in 13% (n=8), subepicardial in 33% (n=20), in a diffuse discontinuous distribution in 11% (n=7), and 5 patients (8%) had >1 of these patterns. In almost all (n=54) of these subjects, CMR provided a final diagnosis.
There was no LGE in 81 patients (49%). In the remaining 22 patients (13%), subtle and nonspecific LGE findings were present.
Tissue Characterization With T2-Weighted Imaging
T2-short tau inversion recovery imaging was available in 80 patients (49%). On visual assessment, there was evidence of myocardial edema (increased signal intensity in short tau inversion recovery images) in only 10 (6%) of the subjectsin 6 cases, this colocalized with LGE in a nonischemic pattern, in 2 with myocardial infarct pattern, and the remaining 2 had no LGE. In 13% (n=22) of subjects, the calculated ratio of short tau inversion recovery signal intensity normalized to skeletal muscle was ≥2.
Imaging-Derived Diagnosis
In 80 cases (49%), CMR findings contributed to determining the underlying pathogenesis for the sCA (Table 3 ). The most frequent diagnoses made from CMR were dilated cardiomyopathy in 27 cases (17%), myocarditis or cardiac sarcoidosis in 22 (13%; 7 of those with possible sarcoidosis), occult myocardial infarction in 13 (8%), and hypertrophic cardiomyopathy in 9 (6%).
Minor and nonspecific changes not suggestive of a specific diagnosis were found in 30 CMR scans (18% of the total, 35% of those without a diagnosis), and 55 patients (34%) had a completely normal scan.
To assess the incremental diagnostic value of CMR, a cardiologist performed an adjudicated review of the clinical history and of the exams, blinded to CMR findings and final diagnosis by the medical team.
There were 50 patients in whom the final clinical diagnosis would not have been made without the additional morphological information and tissue characterization derived from the CMR scan. These included myocarditis (n=14), sarcoidosis (n=7), occult myocardial infarction (n=12), arrhythmogenic right ventricular dysplasia (n=3), nonischemic dilated cardiomyopathy (n=11 cases where CMR was required to exclude alternative differential diagnoses), and 3 other cases where the final clinical diagnoses required exclusion of other CMR-detectable pathology.
It was also judged to be relevant to support other diagnosis, for example, hypertrophic cardiomyopathy.
Electrophysiology Findings and Diagnoses
An arrhythmic pathology was found in 26 cases and deemed to be the main cause for the sCA in 23 cases (14%): 13 patients had a channelopathy, 5 an accessory pathway, and 5 an acquired arrhythmia with a reversible cause.
Final Clinical Diagnosis
After combining all clinical, imaging, and electrophysiology findings, the most frequent final diagnoses made by the physicians were dilated cardiomyopathy, myocarditis, and prior myocardial infarction (Table 3 ). In 59 cases (36%), the clinicians felt that a specific diagnosis could not be determined; 41% of these were presumed to be idiopathic ventricular tachycardia/ ventricular fibrillation according to the medical records. In 12 patients, >1 cause for the sCA was found, but one was felt to be predominant and was considered the final diagnosis (Table 3) .
Follow-Up: Patient Outcomes
Over a median follow-up of 32 months (interquartile range, 17-52), MACE occurred in 51 patients (31%). In 47 patients (27%), a significant nonfatal ventricular arrhythmic event was recorded.
A total of 9 patients (5.2%) died; 2 did not have an ICD, unfortunately we could not adjudicate the cause of death based on the available data. In 5 cases with ICD, a significant arrhythmic event had already been treated by the device before their death. An ICD complication was registered in 15 patients during follow-up (infection in 1, extrusion in 2, inappropriate shocks in 4, and lead displacement in 7 patients; 1 patient had infection, extrusion, and inappropriate shocks). Notably, the 50 patients without an ICD had fewer registered MACE-8% LGE quantification as % of LV mass 0.001 (4) 0.001 (3) 3.0 (11) 0.022* Results are presented as median (interquartile range) or as a percentage. BSA indicates body surface area; CMR, cardiovascular magnetic resonance; EGEr, early gadolinium enhancement ratio; LGE, late gadolinium enhancement; LV, left ventricle; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction (measured on short axis stack pictures; using the biplane method, on 4-chamber and 2-chamber views); LVESV, left ventricular end-systolic volume; MACE, major adverse cardiac events (potentially fatal arrhythmia or death); MAPSE, mitral annular plane systolic excursion; RV, right ventricle; RVEDV, right ventricular end-diastolic volume; RVEF, right ventricular ejection fraction; RVESV, right ventricular end-systolic volume; RWMA, regional wall motion abnormalities; STIR, short tau inversion recovery; and TAPSE, tricuspid annular plane systolic excursion.
*Parameters significantly associated with MACE, with p value<0.1 (considered for the multivariable analysis). †Early gadolinium enhancement ratio (EGEr)-normalized to the skeletal muscle. ‡T2-weighted STIR (short tau inversion recovery) ratio of signal intensity normalized to skeletal muscle. §Increased signal intensity in STIR images clearly seen visually. ║Small or poorly defined patches of LGE (≤1% of total myocardium). CMR in Sudden Cardiac Arrest Survivors versus 41%, P=0.008 (Cox regression). Most cases who did not get an ICD were driven by a conclusion that the underlying cause had resolved or could be managed with appropriate medication or because of patient refusal or loss of follow-up. The final diagnosis and extension of LGE were not significantly different, but LVEF was higher (58% versus 56%; P=0.041) and the presence of LGE was less common (24% versus 44%; P=0.022) in patients without an ICD. As far as we could determine, none of the patients included was totally dependent or in a vegetative state at the time of discharge. However, a standardized evaluation of their neurological status was not available.
Clinical Outcomes
There was no statistically significant relationship between MACE and baseline demographic characteristics, conventional cardiovascular risk factors, or clinical features of the sCA periarrest (Table 1) .
MACE were seen in 41% of the 80 patients with a CMR diagnosis, in 13% of the 23 with a predominant electrophysiology diagnosis, and in 25% of the 59 with idiopathic sCA.
There was a nonsignificant trend toward lower MACE in the group with idiopathic sCA compared with those with a final pathogenic diagnosis (24% versus 34%; P=0.338).
Having a CMR-defined diagnosis was significantly associated with more MACE (41% versus 21%; P=0.022) and a shorter event-free survival (Figure 1 ). Considering the most common diagnoses, MACE occurred in 41% of patients with dilated cardiomyopathy and in 43% of those with myocarditis/sarcoidosis (50% of patients with myocarditis and 29% of those with sarcoidosis), 50% of those with missed myocardial infarct, and 38% with hypertrophic cardiomyopathy (Table 2 ). In the 24 patients with an arrhythmic pathogenesis, there was significantly lower MACE when compared with all other patients (13% versus 34%; P=0.034).
We did not find a statistically significant association between individual diagnoses and prognosis.
In the cohort as a whole, several CMR parameters were associated with MACE in the univariable analysis (Table 2) . These included the presence and extent of LGE (Figure 2 The pattern of LGE (ischemic versus non ischemic) was not significantly related to the occurrence of MACE.
Two methods of multivariable analysis for predicting MACE were considered. Covariates included LVEF, RVEF, and LGE, all significantly associated with MACE in the univariable analysis. Ventricular volumes were not included in the model (to avoid collinearity because ejection fraction was included and derives from end-diastolic and end-systolic left ventricular volumes). A significant interaction between LVEF and RVEF in predicting MACE was excluded. We also included age and sex in the model (Methods section). We tested 2 models, using LGE as either a binary (clearly present or absent) or a continuous variable (% of myocardial mass).
RVEF was independently associated with MACE in both models (Tables I and II in the Data Supplement) . MACE rates were similar in patients with subtle/nonspecific changes and those with a totally normal scan (respectively, 20% and 22%). This lack of association between outcome and nonspecific CMR changes remained when cases diagnosed with a primary arrhythmic cause were excluded (21% versus 25%; P=0.769) and when studying only cases without a final diagnosis.
Discussion
To date, this is the largest published cohort of cardiac arrest survivors in whom coronary disease had been excluded as the cause by coronary angiogram. By incorporating CMR into the diagnostic algorithm for investigation of sCA, the pathogenesis was determined in nearly two thirds of patients, with the most common causes in this cohort being nonischemic dilated cardiomyopathy, myocarditis, and missed myocardial infarction. The prognosis after sCA, however, remains poor, with MACE in ≈1 in 3 within a median follow-up of <3 years, In 12 patients, there were multiple diagnoses made; however, all patients were given one final clinical diagnosis thought to be the main cause of the arrhythmic event. ARVD indicates arrhythmogenic right ventricular dysplasia; CMR, cardiovascular magnetic resonance; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; IHD, ischemic heart disease; and MACE, major adverse cardiac events.
despite defibrillator implantation in 70%. Those with a CMRdefined diagnosis had especially high MACE rates, with the presence of LGE and particularly RVEF as independent predictors of future events.
Worldwide, CAD is the leading cause for sCA, 26 hence coronary angiography is frequently recommended, particularly if an acute coronary syndrome is suspected. 27, 28 CMR is not specifically recommended in recent cardiac arrest guidelines although the indication for a thorough investigation to find a pathogenesis was reinforced. 27, 28 Previous studies investigating causes of sCA (without systematic use of CMR) have mainly focused on manifestations of CAD. 29 Dilated cardiomyopathy has been the second most frequent cause of sCA observed in adults. 4 The few studies that extensively explore the nonischemic causes of sCA are mainly in children or young athletes, with hypertrophic cardiomyopathy/left ventricular hypertrophy usually the most common pathogenesis while myocarditis and congenital coronary abnormalities are more common than in older cohorts. 10, 30 In those studies, most of them postmortem, between 5% and 18% of the cases had no identifiable pathogenesis, 2, 10, [30] [31] [32] reaching around a third of the patients in studies with survivors. 13, 14 This often leaves patients, their families, and clinicians with significant uncertainty on clinical management. A diagnostic approach with routine use of CMR and upstream angiography seems to be a successful method for determining the pathogenesis with CMR alone providing a cause in nearly half of patients. The relatively unique ability of CMR to perform tissue characterization allows detection of myocardial edema and focal scar, enabling identification of many conditions that are difficult to diagnose using other modalities. Our results show that CMR, being able to give information about RVEF and LGE, offers additional prognostic value compared with echocardiographic findings.
CMR was crucial for the main final clinical diagnosis in 50 cases (30%) while it gave an important contribution to all the other cases where it was diagnostic. Cases of myocardial inflammation and specially occult myocardial infarct would not have been detected without CMR's tissue characterization. CMR was also pivotal in the diagnosis of arrhythmogenic right ventricular dysplasia. In fact, CMR can help confirm a diagnosis, suggest a hitherto unexpected diagnosis, and contribute to eliminate differential diagnoses.
These data also highlight the wide range of potential causative underlying diseases in sCA or periarrest cases and illustrate the importance of identifying a diagnosis to facilitate treatment, prognosis, and family screening. Despite all subjects having undergone coronary angiography and echocardiography, the frequency of occult infarcts was high; CMR provides a sensitive method for detection and enables administration of appropriate secondary preventative therapies. A recent study of 137 cardiac arrest survivors 13 without a clear diagnosis before performing CMR reported a higher prevalence of myocardial infarction (58% of patients), possibly related to the application of different angiographic criteria for inclusion (we excluded coronary disease with any stenosis >30%).
From our data, over 1 in 4 subjects were diagnosed with a potential inherited condition and 1 in 5 had an acquired cause, thereby facilitating targeted family screening and genetic testing. This not only helps to diagnose subclinical conditions in family members but also to alleviate concern in family members of those with noninherited conditions.
Patients with an identified pathogenesis for their sCA had a worse prognosis than those labeled as idiopathic ventricular fibrillation, with higher event rates in those with structural or functional cardiac abnormalities identified by CMR. Similar to studies of specific cardiomyopathies, the presence of LGE, lower LVEF, and RVEF were associated with shorter eventfree survival.
LGE extent was not prognostic in this cohort although this may be because of study power or the method for scar quantification used. 22, 33, 34 However, over a third of the cohort received no pathogenic cardiac diagnosis, and these patients remain a difficult Figure 1 . Kaplan-Meier curves displaying the event-free survival according to the findings in cardiovascular magnetic resonance (CMR): patients with a CMRdefined diagnosis had a worse prognosis than those with a normal scan or one with minor nonspecific changes (P=0.018 in the log-rank test; hazard ratio=2; 95% confidence interval=1.1-3.5).
group to manage clinically, particularly given the high MACE rates of 1 in 4. In other studies with sCA survivors, the percentages of cases without a final determined diagnosis are identical to ours. 13, 14 Therefore, given the high recurrence of events and lack of ability to identify truly low-risk patients, ICD implantation must always be considered in these patients.
Our data also demonstrate that cardiac arrest and resuscitation do not necessarily produce detectable changes by CMR. This means that if changes are seen in a CMR scan in this context, we cannot assume that they are solely because of consequences of the arrest per se. However, subtle nonspecific CMR abnormalities did not influence prognosis.
Limitations and Strengths
This is a retrospective study that used a relatively standardized approach to survivors of cardiac arrests, and CMR exams were blindly reviewed by at least 2 observers.
Given the design of the study, we can only derive association between the CMR findings and sCA; causality can only be hypothesized.
Nonsurvivors were not included, and diseases with a more malignant course may, therefore, be under-represented. Patients with a presumed coronary pathogenesis for their arrests were excluded, and this may have included patients with dual pathology or bystander coronary disease. Patients who could not undergo CMR because of hemodynamic instability, functional deficits that precluded breath-holding, severe renal failure, claustrophobia, or magnetic devices were also excluded.
Validation of CMR tissue characterization is currently incomplete. Notably, endomyocardial biopsy was not performed as a component of this clinical pathway and might have added valuable additional information.
The cohort size prevents more detailed study of pathogenic subgroups, and we must be cautious in interpreting the prognostic value of individual CMR parameters (including ejection fraction and LGE) without first considering them within a diagnostic framework.
Finally, we analyzed all-cause mortality rather than cardiovascular death because the exact cause of death could not be determined in most cases.
Conclusions
By incorporating CMR in clinical pathway for investigation of sCA in the absence of CAD, a cause can be identified in nearly two thirds of patients. Many of the most frequent pathogeneses identified using CMR (idiopathic dilated cardiomyopathy, myocarditis, and occult myocardial infarction) have important implications with regard to specific clinical management, family screening, and prognosis. Although the risk of recurrent ventricular arrhythmias and death is high across this patient population, patients diagnosed with a structural or functional cardiac abnormality by CMR had a 2-fold increased risk.
LGE and biventricular systolic function were associated with prognosis, with RVEF being an independent predictor. We, therefore, advocate consideration of CMR for investigation and prognostication of all patients without culprit coronary disease post-sCA. Kaplan-Meier curves of the major adverse cardiac events-free survival according to the presence of late gadolinium enhancement (LGE), which showed a significant relationship (logrank test P=0.014; hazard ratio=1.9; 95% confidence interval=1.1-3.4 in Cox regression).
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